Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects
Introduction
Many papers published on non-alcoholic steatohepatitis (NASH) have included subjects with chronic liver damage from a variety of causes [1], [2], [3], [4], [5], [6]. In clinical practice, the interest in this syndrome is owing to the presence of NASH in subjects with routine drug use or exposure to toxins, or with obesity or rapid weight loss, all conditions of emerging social importance [7], [8], [9], [10], [11], [12], [13]. Researchers are also attracted to this syndrome because its pathogenic mechanisms suggest how liver steatosis, through necrosis and inflammation, may lead to fibrosis and cirrhosis [14], [15]. The appearance of NASH is related, in animals and humans, to enhanced lipid peroxidation, mitochondrial dysfunction, altered iron, lipid and carbohydrate metabolism [5], [6], [14], [15], [16], [17]. However, despite the large number of papers published, few studies have aimed at simultaneously defining the different clinical, histological, pathogenic, and therapeutic aspects of non-alcoholic fatty liver disease (NAFLD).
Our country is characterized by a high prevalence of hepatitis B or C virus (HBV, HCV) infection [18] and high alcohol consumption/capita per year [19]. Nonetheless, about 3–5% of liver patients/year, observed at the Liver Units of our Departments from 1996 to 1999, tested negative for the leading known causes of chronic liver disease [20].
We held this study to characterize these patients by evaluating the clinical aspects, type of liver damage, and the relationships occurring among liver histology, body weight, insulinemia, parameters of oxidative stress, and iron, lipid and carbohydrate metabolism.
Section snippets
Patients and methods
The study protocol, according to Helsinki criteria, was approved by the Ethic Committee of our Department. All patients had given informed consent for participation.
Eighty-four subjects were selected from 2100 patients who were being observed at our units for liver problems according to the following criteria: (1), abnormally high plasma aminotransferase (AST and ALT) and/or gamma-glutamyl-transpeptidase (γGT) levels for at least 12 months; (2), presence/absence of ultrasonographic bright
Clinical aspects
The main clinical data of participants are summarized in Table 1. Subjects were predominantly male. When compared, their median age resulted in being lower than that of the female subjects. In 58/66 men (87.8%) and in 17/18 women (94.4%), the BMI was above normal values reported for our country [25] (median value in both sexes, 26.7; range, 19.53–32.31). Clear obesity was found only in four patients, while none claimed to have recent weight loss or variations in their dietary regimen and/or
Discussion
There are four major results of our study: (1), NAFLD, ranging from steatosis to NASH or cirrhosis, was present in approximately 5% of patients observed at our liver units; (2), we have described its primary clinical characteristics; (3), we have demonstrated the relationships occurring among liver histology, BMI, insulinemia, iron, lipid and carbohydrate metabolism, and parameters of oxidative stress; and (4), we have given a preliminary suggestion for possible dietetic and/or therapeutic
References (48)
- et al.
Non-alcoholic steatohepatitis: an expanded clinical entity
Gastroenterology
(1994) - et al.
Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance
J Hepatol
(1998) - et al.
General aspects of drug-induced liver disease
Gastroenterol Clin North Am
(1995) - et al.
Acute and chronic steatosis lead to in vivo lipid peroxidation in mice
J Hepatol
(1996) - et al.
Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation
J Hepatol
(1997) - et al.
Attributable risk for symptomatic liver cirrhosis in Italy
J Hepatol
(1998) - et al.
Mitochondrial abnormalities in non-alcoholic steatohepatitis
J Hepatol
(1999) - et al.
Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
Gastroenterology
(1996) - et al.
Cytochrome P450 2E1 inducibility and hydroxyethyl radical formation among alcoholics
J Hepatol
(1998) - et al.
Role of cytochrome P450 2E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol
Hepatology
(1996)
Non-alcoholic steatohepatitis
Med Clin North Am
Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis
Gastroenterology
Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
J Hepatol
Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study
Hepatology
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years
Hepatology
Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
Dig Dis Sci
The natural history of nonalcoholic fatty liver: a follow-up study
Adv Gastroenterol Hepatol Clin Nutr
Nonalcoholic steatohepatitis
Ann Intern Med
Smokeless tobacco-induced increase in hepatic lipid peroxidation. DNA damage and excretion of urinary lipid metabolites
Int J Exp Pathol
Forward and reverse catalysis and product sequestration by human glutathione-S-transferase in the reaction of GSH with dietary aralkyl isothiocyanate
Biochem J
Aflatoxin exposure in human populations: measurements and relationship to cancer
CRC Crit Rev Toxicol
Nonalcoholic steatohepatitis in obesity. A reversible condition
Acta Med Scand
Liver pathology in morbidly obese patients with and without diabetes
Am J Gastroenterol
Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss
Diabetes Metab
Cited by (172)
Ferritinophagy: A new idea for liver diseases regulated by ferroptosis
2024, Hepatobiliary and Pancreatic Diseases InternationalEmerging role of regulated cell death in intestinal failure-associated liver disease
2023, Hepatobiliary and Pancreatic Diseases InternationalThe gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin–linked MAFLD
2022, Free Radical Biology and MedicineAn overview of ferroptosis in non-alcoholic fatty liver disease
2022, Biomedicine and PharmacotherapyCitation Excerpt :Li et al. used transmission electron microscopy to analyze the morphology of mitochondria in liver cells and observed ferroptosis in a methionine/choline-deficient (MCD) diet-induced NASH model [53]. The levels of the secondary products of lipid peroxidation MAD and 4-HNE are much higher in NASH patients than in patients with hepatic steatosis alone [140], and they are commonly used as indicators in studies of ferroptosis [141]. Trolox, a ferroptosis inhibitor, and deferiprone (DFP), an iron chelator, almost completely inhibited necrotic cell death, inflammatory cell infiltration, and inflammatory cytokine expression [142].